Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 22, 2011"AFib in America: State Impact Reports" Illustrate the Disconnect Between AFib's Impact and the Public Health Resources Available
-
Mar 9, 2011The Coalition to Prevent DVT Promotes Education to Fill the Gap between DVT Risk and Co-Morbid Patients
-
Feb 23, 2011Sanofi Pasteur stands shoulder to shoulder with Rotary International during NYSE and EURONEXT bell-ringing ceremonies
-
Feb 16, 2011- WNBA, NBA Development League and NBA All-Star Dwight Howard, WNBA All-Star Alana Beard and NBA Legends Walt Frazier and Chris Dudley will also Raise Awareness about Diabetes -
-
Feb 16, 2011Combination will enhance sanofi-aventis' sustainable growth strategy by expanding its footprint in biotechnology
-
Feb 9, 2011
-
Jan 12, 2011- First industry partner for UCSF's Program for Breakthrough Biomedical Research (PBBR) -
-
Dec 17, 2010- Collaboration promotes clinical and translational research to address unmet needs of cancer patients in India -
-
Dec 9, 2010Final 10-year combination chemotherapy adjuvant survival data, studies of investigational agent iniparib to be featured at breast cancer symposium
-
Nov 29, 2010Vaccine against one of the most common causes of hospital-acquired infection in North America & Europe tested in the U.S.
-
Oct 28, 2010
-
Oct 25, 2010Investigational Intradermal Influenza Vaccine Induced Comparable Immune Responses to Licensed Fluzone Vaccine with Less Antigen, Smaller Injection Volume
-
Oct 18, 2010- Focused on translational biomedical research in multiple therapeutic areas such as cancer, diabetes and inflammation -
-
Oct 8, 2010World’s Largest Influenza Vaccine Producer Awarded $57 Million To Maintain Year-Round Egg Supply for Influenza Pandemic Planning
-
Oct 1, 2010- Results of the Phase III TROPIC global study published -
-
Sep 27, 2010Technology of in-vitro Models of the Human Immune System to Provide Competitive Advantage in Vaccine Development
